Brief: Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
08/07/2024 13:22
July 8 (Reuters) - Merus NV 2GH.F :
* MERUS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 TRIAL OF
PETOSEMTAMAB IN 2L CRC
* MERUS NV - PHASE 2 TRIAL TO ENROLL APPROXIMATELY 40
PATIENTS
Source text for Eikon: ID:nGNX5wrxTS
Further company coverage: 2GH.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab